CKPT Checkpoint Therapeutics Inc.

1.2
-0.03  -2%
Previous Close 1.23
Open 1.28
Price To Book 3.53
Market Cap 66,046,207
Shares 55,038,506
Volume 197,012
Short Ratio
Av. Daily Volume 227,807
Stock charts supplied by TradingView

NewsSee all news

  1. Checkpoint Therapeutics Reports Full-Year 2019 Financial Results and Recent Corporate Highlights

    NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and

  2. Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

    FDA feedback supports plan to submit Biologics License Application (BLA) based on data from ongoing Phase 1 trialOne-third enrollment complete in cohort of patients with metastatic cutaneous squamous cell

  3. Checkpoint Therapeutics Announces Pricing of Public Offering of Common Stock

    NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the pricing of its previously

  4. Checkpoint Therapeutics Announces Proposed Public Offering of Common Stock

    NEW YORK, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it is proposing to offer and

  5. Checkpoint Therapeutics Announces Presentation of Anti-PD-L1 Cosibelimab Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that new pharmacokinetic and target

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 enrolment to be completed by end of 2020. Estimate data 1H 2021. BLA filing due 2021.
CK-101
Cutaneous Squamous Cell Carcinoma

Latest News

  1. Checkpoint Therapeutics Reports Full-Year 2019 Financial Results and Recent Corporate Highlights

    NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and

  2. Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

    FDA feedback supports plan to submit Biologics License Application (BLA) based on data from ongoing Phase 1 trialOne-third enrollment complete in cohort of patients with metastatic cutaneous squamous cell

  3. Checkpoint Therapeutics Announces Pricing of Public Offering of Common Stock

    NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the pricing of its previously

  4. Checkpoint Therapeutics Announces Proposed Public Offering of Common Stock

    NEW YORK, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it is proposing to offer and

  5. Checkpoint Therapeutics Announces Presentation of Anti-PD-L1 Cosibelimab Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that new pharmacokinetic and target

  6. Checkpoint Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

    NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage, immunotherapy and targeted oncology company, today announced financial results and recent

  7. Checkpoint Therapeutics Announces Presentation of Positive Interim Clinical Results for Anti-PD-L1 Cosibelimab at the European Society for Medical Oncology (ESMO) Congress 2019

    50% objective response rate observed in cutaneous squamous cell carcinoma (CSCC)40% objective response rate observed in non-small cell lung cancerWell-tolerated safety profile across all cohortsEnrollment ongoing to

  8. Checkpoint Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and

  9. Checkpoint Therapeutics Announces Data Presentation at the European Society for Medical Oncology (ESMO) Congress 2019

    NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and

  10. Checkpoint Therapeutics to Present at September 2019 Investor Conferences

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and